EFG Asset Management North America Corp. Purchases 37,061 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

EFG Asset Management North America Corp. grew its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 99.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 74,190 shares of the biopharmaceutical company’s stock after buying an additional 37,061 shares during the period. Intra-Cellular Therapies accounts for 0.8% of EFG Asset Management North America Corp.’s investment portfolio, making the stock its 24th largest position. EFG Asset Management North America Corp. owned about 0.07% of Intra-Cellular Therapies worth $6,200,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in Intra-Cellular Therapies by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 9,721,360 shares of the biopharmaceutical company’s stock worth $811,928,000 after purchasing an additional 93,107 shares during the period. Wasatch Advisors LP lifted its stake in shares of Intra-Cellular Therapies by 3.5% during the 3rd quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company’s stock valued at $281,601,000 after buying an additional 130,351 shares in the last quarter. Bellevue Group AG boosted its holdings in Intra-Cellular Therapies by 0.6% in the 3rd quarter. Bellevue Group AG now owns 2,485,627 shares of the biopharmaceutical company’s stock worth $181,873,000 after buying an additional 14,342 shares during the period. State Street Corp grew its stake in Intra-Cellular Therapies by 3.1% in the 3rd quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company’s stock valued at $136,017,000 after buying an additional 56,664 shares in the last quarter. Finally, Franklin Resources Inc. raised its holdings in Intra-Cellular Therapies by 9.7% during the 3rd quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company’s stock valued at $129,463,000 after acquiring an additional 155,655 shares during the period. Institutional investors own 92.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ITCI shares. StockNews.com began coverage on Intra-Cellular Therapies in a report on Thursday, March 20th. They issued a “hold” rating for the company. Canaccord Genuity Group downgraded Intra-Cellular Therapies from a “buy” rating to a “hold” rating and raised their target price for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Piper Sandler reiterated a “neutral” rating and set a $132.00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Cantor Fitzgerald upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 14th. Finally, Mizuho lowered shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $140.00 to $132.00 in a report on Monday, February 24th. Ten investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $106.08.

Intra-Cellular Therapies Stock Up 0.0 %

NASDAQ ITCI opened at $131.70 on Tuesday. The stock’s 50-day simple moving average is $128.70 and its two-hundred day simple moving average is $98.18. Intra-Cellular Therapies, Inc. has a twelve month low of $64.09 and a twelve month high of $131.71. The company has a market capitalization of $14.00 billion, a price-to-earnings ratio of -151.38 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million for the quarter, compared to analysts’ expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. On average, equities analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.